Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy

PURPOSE: Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r/r) aggressive B-cell lymphomas. The prognosis of patients who relapse after CAR-T cell treatment is dismal and factors predicting outcomes need to be identified. Our aim was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgi, Thomas Walter, Kurch, Lars, Franke, Georg-Nikolaus, Jentzsch, Madlen, Schwind, Sebastian, Perez-Fernandez, Carmen, Petermann, Naima, Merz, Maximilian, Metzeler, Klaus, Borte, Gudrun, Hoffmann, Sandra, Herling, Marco, Denecke, Timm, Kluge, Regine, Sabri, Osama, Platzbecker, Uwe, Vučinić, Vladan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356653/
https://www.ncbi.nlm.nih.gov/pubmed/36662305
http://dx.doi.org/10.1007/s00432-023-04587-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356653/
https://www.ncbi.nlm.nih.gov/pubmed/36662305
http://dx.doi.org/10.1007/s00432-023-04587-4

Ejemplares similares